{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:48:13Z","timestamp":1789850893803,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.beha.2012.04.007","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T08:50:15Z","timestamp":1337158215000},"page":"133-141","source":"Crossref","is-referenced-by-count":31,"title":["Proteasome inhibitors in mantle cell lymphoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Beata","family":"Holkova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beha.2012.04.007_bib1","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.1997.15.4.1664","article-title":"Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants","volume":"15","author":"Majlis","year":"1997","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2012.04.007_bib2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2012.04.007_bib3","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle\u2013cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2012.04.007_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3816\/CLM.2001.n.003","article-title":"A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma","volume":"1","author":"Wilder","year":"2001","journal-title":"Clin Lymphoma"},{"issue":"3","key":"10.1016\/j.beha.2012.04.007_bib5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/annonc\/mdh093","article-title":"Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study","volume":"15","author":"Jermann","year":"2004","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.beha.2012.04.007_bib6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2012.04.007_bib7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2012.04.007_bib8","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.beha.2012.04.007_bib9","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2012.04.007_bib10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2012.04.007_bib11","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2012.04.007_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.leu.2402417","article-title":"The proteasome: a novel target for cancer chemotherapy","volume":"16","author":"Almond","year":"2002","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2012.04.007_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.leu.2404444","article-title":"Proteasome inhibitors: antitumor effects and beyond","volume":"21","author":"Nencioni","year":"2007","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.beha.2012.04.007_bib14","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2008-07-171637","article-title":"Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors","volume":"113","author":"Kuhn","year":"2009","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2012.04.007_bib15","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/jnci\/djr160","article-title":"Novel proteasome inhibitors to overcome bortezomib resistance","volume":"103","author":"Ruschak","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.beha.2012.04.007_bib16","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/sj.cdd.4400436","article-title":"Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts","volume":"5","author":"An","year":"1998","journal-title":"Cell Death Differ"},{"issue":"5","key":"10.1016\/j.beha.2012.04.007_bib17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"5852","key":"10.1016\/j.beha.2012.04.007_bib18","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1126\/science.1146361","article-title":"IRE1 signaling affects cell fate during the unfolded protein response","volume":"318","author":"Lin","year":"2007","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.beha.2012.04.007_bib19","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1158\/0008-5472.CAN-05-2961","article-title":"Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells","volume":"66","author":"Nawrocki","year":"2006","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.beha.2012.04.007_bib20","doi-asserted-by":"crossref","first-page":"9946","DOI":"10.1073\/pnas.1334037100","article-title":"Proteasome inhibitors disrupt the unfolded protein response in myeloma cells","volume":"100","author":"Lee","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"36","key":"10.1016\/j.beha.2012.04.007_bib21","doi-asserted-by":"crossref","first-page":"33714","DOI":"10.1074\/jbc.M302559200","article-title":"Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells","volume":"278","author":"Ling","year":"2003","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.beha.2012.04.007_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.yexcr.2004.02.001","article-title":"The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib","volume":"295","author":"Yu","year":"2004","journal-title":"Exp Cell Res"},{"issue":"4","key":"10.1016\/j.beha.2012.04.007_bib23","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2010-04-278853","article-title":"The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in\u00a0vitro and in\u00a0vivo by down-regulation of the prosurvival ER chaperone BiP\/Grp78","volume":"117","author":"Roue","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2012.04.007_bib24","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.beha.2012.04.007_bib25","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"issue":"43","key":"10.1016\/j.beha.2012.04.007_bib26","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","article-title":"Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function","volume":"22","author":"Luciano","year":"2003","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.beha.2012.04.007_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"5240","key":"10.1016\/j.beha.2012.04.007_bib28","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1126\/science.270.5240.1326","article-title":"Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis","volume":"270","author":"Xia","year":"1995","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.beha.2012.04.007_bib29","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1158\/1535-7163.MCT-05-0222","article-title":"Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin","volume":"4","author":"Vaziri","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.beha.2012.04.007_bib30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/0008-5472.CAN-05-1195","article-title":"Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells","volume":"66","author":"Roccaro","year":"2006","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.beha.2012.04.007_bib31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell."},{"issue":"9","key":"10.1016\/j.beha.2012.04.007_bib32","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2012.04.007_bib33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell."},{"issue":"8","key":"10.1016\/j.beha.2012.04.007_bib34","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.bjc.6603406","article-title":"A novel proteasome inhibitor NPI-0052 as an anticancer therapy","volume":"95","author":"Chauhan","year":"2006","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.beha.2012.04.007_bib35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"Perez-Galan","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2012.04.007_bib36","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1080\/10428190801910912","article-title":"Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways","volume":"49","author":"Rizzatti","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.beha.2012.04.007_bib37","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","article-title":"The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak","volume":"109","author":"Perez-Galan","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2012.04.007_bib38","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2007-12-130781","article-title":"The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies","volume":"112","author":"Paoluzzi","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2012.04.007_bib39","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.leu.2404511","article-title":"Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma","volume":"21","author":"Weigert","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2012.04.007_bib40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.leu.2404959","article-title":"Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in\u00a0vitro and in\u00a0vivo","volume":"22","author":"Wang","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.beha.2012.04.007_bib41","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2003-03-0737","article-title":"The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase\u00a0inhibitors to induce apoptosis in Bcr\/Abl+ cells sensitive and resistant to STI571","volume":"102","author":"Yu","year":"2003","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2012.04.007_bib42","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.beha.2012.04.007_bib43","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.beha.2012.04.007_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0609.2007.00995.x","article-title":"Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma","volume":"80","author":"Heider","year":"2008","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2012.04.007_bib45","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1078-0432.CCR-09-1937","article-title":"Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma","volume":"16","author":"Paoluzzi","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.beha.2012.04.007_bib46","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1158\/1078-0432.CCR-10-0529","article-title":"Role of CAAT\/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells","volume":"16","author":"Rao","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.beha.2012.04.007_bib47","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1182\/blood-2009-12-257261","article-title":"The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in\u00a0vitro and in\u00a0vivo","volume":"115","author":"Dasmahapatra","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2012.04.007_bib48","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1535-7163.MCT-10-1108","article-title":"Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in\u00a0vitro and in\u00a0vivo","volume":"10","author":"Dasmahapatra","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.beha.2012.04.007_bib49","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood-2010-02-269514","article-title":"Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2012.04.007_bib50","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in\u00a0vitro sensitivity and tumor necrosis factor alpha response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2012.04.007_bib51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150","volume":"18","author":"Belch","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.beha.2012.04.007_bib52","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.beha.2012.04.007_bib53","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2012.04.007_bib54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2012.04.007_bib55","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.beha.2012.04.007_bib56","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1002\/cncr.25509","article-title":"Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma","volume":"116","author":"Furman","year":"2010","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.beha.2012.04.007_bib57","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2012.04.007_bib58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2010.08315.x","article-title":"Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma","volume":"151","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2012.04.007_bib59","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10428190902856790","article-title":"A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study","volume":"50","author":"Weigert","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2012.04.007_bib60","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8553","article-title":"Phase I dose escalation study of fludarabine, bortezomib, and rituximab for relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma","author":"Barr","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2012.04.007_bib61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4161\/mabs.1.1.7472","article-title":"Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma","volume":"1","author":"Alinari","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.beha.2012.04.007_bib62","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.4944.4944","article-title":"A phase I study of bortezomib (Velcade\u00ae) plus 90yttrium Labeled ibritumomab Tiuxetan (Zevalin\u00ae) in patients with relapsed or refractory B-Cell non-Hodgkin lymphoma (NHL)","author":"Beaven","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.007_bib63","doi-asserted-by":"crossref","unstructured":"Holkova B, Perkins EB, Sokol L, Richards KL, Parekh S, Elstrom R, et\u00a0al. A phase II trial of bortezomib and vorinostat in mantle cell lymphoma and diffuse large B-Cell lymphoma. Blood (ASH Annual Meeting Abstracts); San Diego, CA 2011.","DOI":"10.1182\/blood.V118.21.779.779"},{"key":"10.1016\/j.beha.2012.04.007_bib64","first-page":"2569","volume":"110","year":"2007"},{"issue":"24","key":"10.1016\/j.beha.2012.04.007_bib65","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692612000345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692612000345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T12:27:30Z","timestamp":1713961650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692612000345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1521692612000345"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2012.04.007","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}